Akademik Veri Yönetim Sistemi
Electrochimica Acta, cilt.539, 2025 (SCI-Expanded, Scopus)
Acute myeloid leukaemia (AML) is an aggressive hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursors in the bone marrow. Gilteritinib (GLT), a potent FLT3 and AXL tyrosine kinase inhibitor, has been approved for the treatment of relapsed or refractory AML. Due to its narrow therapeutic window, potential drug–drug interactions, and associated toxicities, the accurate and sensitive monitoring of GLT in biological matrices is crucial for effective therapy management. In this study, a novel electrochemical sensor was fabricated for the first-time determination of GLT using a glassy carbon electrode (GCE) modified with a NiCaCr-LTH@Nb₂C MXene nanocomposite. The electrode material was thoroughly characterized by Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD), Field Emission Scanning Electron Microscopy (FE-SEM), Energy Dispersive X-ray Spectroscopy with FE-SEM (FE-SEM-EDX), EDX-mapping, Brunauer–Emmett–Teller (BET) Analysis, and Thermogravimetric Analysis (TGA) techniques. The sensor exhibited a wide linear range (0.005–11.640 µM), a low detection limit (LOD) (0.001 µM), and excellent reproducibility with RSD values below 1.5%. The developed sensor demonstrated high selectivity against common biological and pharmaceutical interferents, and was successfully applied to human plasma, urine, and pharmaceutical tablets with recoveries ranging from 99.52% to 101.48% and RSDs under 1.32%. Additionally, the method's greenness and environmental compatibility were confirmed using the AGREE, GAPI, and BAGI assessment tools.